Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 1, 1997, Pages 74-83

  Gould, I M ^a  

^a NHS GRAMPIAN   (United Kingdom)

Author keywords

Beta lactam dosing; Pharmacodynamics; Post antibiotic effect

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BACITRACIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFACLOR; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; GLYCOPEPTIDE; GYRASE INHIBITOR; LORACARBEF; MECILLINAM; MEROPENEM; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TEICOPLANIN; TICARCILLIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; CONFERENCE PAPER; DRUG PROTEIN BINDING; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PHARMACODYNAMICS; POSTANTIBIOTIC EFFECT;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; LACTAMS; MICROBIAL SENSITIVITY TESTS;

EID: 0030747723     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian, V. eds. Antibiotics in Laboratory Medicine, 2nd ed. Baltimore, Williams and Wilkins, 1986: 515-34.
2. Gould IM, Jason AC, Milne K. Studies on antibiotic effect using the malthus microbial growth analyser with special reference to the post antibiotic effect of imipenem. J Antimicrob Chemother 1989; 24: 523-531.
3. Maller R, Isaksoon B, Nilsson L, Soren L. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother 1988; 22: 75-79.
4. Fan ST, Lau W, Teoh-Chan CH, Lau KF, Mauracher FH. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidaxole, in gangrenous and perforated appendicitis. J Antimicrob Chemother 1988; 22: 69-74.
5. MacKenzie FM, Gould IM. The post antibiotic effect. J Antimicrob Chemother 1993; 32: 519-537.
6. Majcherczyk PA, Kunz S, Hattenberger M, Vaxelaire J, Zak O, O'Reilly T. Isolation and in-vitro and in-vivo characterisation of a mutant of Pseudomas aeruginosa PAO1 that exhibited a reduced postantibiotic effect in response to imipenem. J Antimicrob Chemother 1994; 34: 485-505.
7. Gudmundsson S, Vogelman B, Craig WA. The in-vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother 1986; 18: 67-73.
8. Renneberg J, Walder M. Antibiotic effects of imipenem. norfloxacin and amikacin in vitro and in vivo. Antimicrob Agents Chemother 1989;33: 1714-1720.
9. Hessen MT, Pitsakis PG, Levison ME. Absence of a postantibiotic effect in experimental Pseudomonas endocarditis treated with imipenem, with or without gentamicin. J Infect Dis 1988; 158: 542-548.
10. Jabes D, Rossi R, Della Brune C. Postantibiotic effect of the oral penem FCE 25199 in vitro and in vivo by a new cage model in mica. International Congress of Antimicrobial Agents and Chemotherapy 1992 Abstr no. 385.
11. Odenholt-Tornqvist I. Pharmacodynamic effects of subinhibitory concentrations of β-lactam antibiotics in vitro. Antimicrob Agents Chemother 1989; 35: 1834-1859.
12. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med 1984; 77: 657-62.
13. Bakker-Woudenberg IAJM, Roosendaal R. Impact of dosage regimens on the efficacy of antibiotics in the immunocompromised host. J Antimicrob Chemother 1988; 21: 145-47.
14. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983; 147: 918-32.
15. Bennett WM, Plamp CE, Gilbert DN, Parker A, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: Dissociation of peak serum levels from renal failure. J Infect Dis 1979; 139: 576-80.
16. Frame PT, Phair JP, Watanakunakorn C, Bannister TWP. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 1977; 135: 952-56.
17. Keiner NE, Bloxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978; 4:85-101.
18. Keating MJ, Bodey M, Valdivieso M, Rodriguez V. A randomised comparative trial of three aminoglycosides - comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine (Baltimore) 1979; 58: 159-170.
19. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy; importance of the ratio of peak con centration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-99.
20. Vogelman B, Gudnumdsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
21. Gerber AU, Brugger HP, Feller C, Stritzko T, Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis 1986; 153: 90-97.
22. Gerber AU, Wiprachtiger P, Stettler-Spichiger U, Lebek G. Constant infusion vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro. J Infect Dis 1982; 145: 554-560.
23. Gould IM, Milne K, Harvey G, Jason C. Ionic binding, adaptive resistance and post antibiotic effect of netilmicin and ciprofloxacin. J Antimicrob Chemother 1991; 27: 741-748.
24. Schentag JJ. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values and bacterial eradication in patients with gram negative pneumonia. Scand J Infect Dis 1991; 71: 218-234.
25. Mouton JW, Vinks AATMM. Is continuous infusion of β lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38: 515.
26. Mordenti JJ, Quintiliani R, Nightingale CH. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J Antimicrob Chemother 1985; 15 (Suppl. A): 313-321.
27. Craig W. Pharmacokinetic and experimental data on beta-lactam antibiotics in treatment of patients. Eur J Clin Microbiol 1984; 3; 575-578.
28. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32: 289-297.
29. Andersen ET, Young LS, Hewitt WL. Simultaneous antibiotic levels in "breakthrough" Gram-negative rod bacteremia. Am J Med 1976; 61: 493-497.
30. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or toramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67: 608-616.
31. Schentag JJ, Smith IL, Swanson DJ et al. Role for dual individualization with cefmenoxime. Am J Med 1984; 77 (Suppl. 6a): 43-50.
32. Feld R, Valdivieso M, Bodey GP, Rodriguez V. (Comparison of amikacin and tobramycin in the treatment of infections in patients with cancer. J Infect Dis 1977; 135: 61-66.
33. Daenen S, De Vries-Hospers H. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion ceftazidime. Lancet 1988; 331: 937.
34. Hanberger H, Nilsson LE, Kihlstrom E, Maller R. Postantibiotic effect of β-lactam antibiotics on Escherichia coli evaluated by bioluminescence assay of bacterial ATP. Antimicrob Agents Chemother 1990; 34: 102-106.
35. MacKenzie FM, Gould IM, Chapman DG, Jason D. Comparison of methodologies used in assessing the postantibiotic effect. J Antimicrob Chemother 1994; 34: 223-230.
36. MacKenzie FM, Gould IM, Chapman DG, Jason D. Postantibiotic effect of meropenem on members of the family Enterobacteriaceae determined by five methods. Antimicrob Agents Chemother 1994; 38: 2583-2589.
37. Hanberger H, Nilsson LE, Nilsson M, Maller R. Postantibiotic effect of beta lactam antibiotics on Gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis 1991; 10: 927-934.
38. Gould IM, Allison K, Milne K, Jason D. Postantibiotic effect of co-amoxyclav against respiratory pathogens. In: Recent Advances in Chemotherapy. American Society for Microbiology. Eds J Einhorn, C Nord, R Norrby 1993: 373-374.
39. Gould IM, Milne K, Allison L, MacKenzie F, Jason D. The postantibiotic effect of amoxycillin, co-amoxyclav and clavulanic acid. In Press. Anti-infective Drugs and Chemotherapy.
40. MacKenzie F, Milne K, Jason A, Gould IM. Relationship between post antibiotic effect, effective regrowth time and morphology of Gram-negative organisms after exposure to cefaclor, loracarbef and cefuroxime. 7th European Society of Clinical Microbiology & Infectious Diseases, Vienna, 1995, abstract n. 537.
41. Hanberger H, Svensson E, Nilsson M, Nilsson LE, Hornsten EG, Mailer R. Effects of imipenem of Escherichia coli studied using bioluminescence viable counting and microscopy. J Antimicrob Chemother 1993; 31: 245-260.
42. Baquero F, Culebras E, Patron C, Perez-Diaz JC, Medrano JC, Vicente MF. Postantibiotic effect of imipenem on Gram-positive and Gram-negative micro-organisms. J Antimicrob Chemother 1986; 18: (Suppl E) 47-59.
43. Hanberger H, Stenhern M, Svensson E, Nilsson LE, Nilsson M. Control Related Effective Regrowth Time (CERT) and Post Antibiotic Effect (PAE) of cefepime on bacteria studied by bioluminescence. 7th European Congress of Clinical Microbiology and Infectious Diseases 1995: Abstract 539.
44. Craig W, Ebert S, Watanabe Y. Differences in time above MIC (T>MIC) required for efficacy of beta-lactams in animal infection models. 33rd International Congress of Antimicrobial Agents and Chemotherapy. 1993 Abstract n. 86.
45. Jacobsson S, Fogh A, Larsson P, Lomborg S. Evaluation of amoxicillin clavulanate twice daily versus thrice daily in the treatment of otitis media in children. Eur J Clin Microbiol 1993; 12: 319-324.
46. Konig C, Simmen HP, Blaser J. High numbers of CFU at onset of therapy compared to inoculum size of in vitro susceptibility tests and implications on bactericidal activity. 36th International Congress ot Antimicrobial Agents and Chemotherapy 1996 Abstract n. D40.
47. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: An explanation for the inoculum effect. J Infect Dis 1993; 167: 1401-1405.
48. Jason AC, MacKenzie FM, Jason D, Gould IM. Automatic procedures for measuring post antibiotic effect and determining random errors. J Antimicrob Chemother 1994; 34; 669-678.
49. Tuomanen E, Schwarz J. Penicillin-binding protein 7 and its relationship to lysis of nongrowing Escherichia coli. J Bacteriol 1987; 169: 4912-4915.
50. Goldstein EJC, Citron DM, Cherubin CE. Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, β-lactamase inhibitor combinations and the penicillin-derived components of these combinations. Antimicrob Agents Chemother 1991; 35: 560-566.
51. Dougherty TJ, Pucci MJ. Penicillin-binding proteins are regulated by rpoS during transitions in growth states of Escherichia coli. Antimicrob Agents Chemother 1994; 38: 204-210.
52. Soriano F, Ponte C, Santamaria M, Jimenez-Arriero M. Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by Escherichia coli. J Antimicrob Chemother 1990; 25: 621-627.
53. Lam YMF, Duroux MH, Gambertoglio JG, Barriere SL, Guglielmo BJ. Effect of protein binding on serum bactericidal activities of ceftazidime and cetoperazone in healthy volunteers. Antimicrob Agents Chemother 1988; 32: 298-302.
54. Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995; 39: 1842-1847.
55. Drusano GL. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis Suppl. 1989; 74: 235-248.
56. Rolinson GN. Effect of β-lactam antibiotics on bacterial cell growth rate. J Gen Microbiol 1980; 120: 317-323.
57. O'Neill CO, Nicolau DP, Nightingale CH, Quintiliani R. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections. Antimicrob Agents Chemother 1994; 38: 1112-1117.
58. Thys JP, Klastersky J, Mombelli G. Peak or sustained antibiotic serum levels for optimal tissue penetration. J Antimicrob Chemother 1981; 8: 29-36.
59. Barza M. Principles of tissue penetration of antibiotics. J Antimicrob Chemother 1981; 8: 7-28.
60. Eagle H, Musselman AD. Slow recovery of bacteria from toxic effects of penicillin. J Bacteriol 1949; 58: 475-490.
61. Eagle H, Fleischman R, Levy M. The effect of the interval between injections on therapeutic efficacy. N Engl J Med 1953; 248: 480-488.